75 related articles for article (PubMed ID: 313321)
1. [Quantitative and functional response of a lymphatic subpopulation during adjuvant intermittent chemo-immunotherapy in breast cancer].
Betzler M; Flad HD; Huget R; Schreml W; Schlag P; Herfarth C
Chir Forum Exp Klin Forsch; 1978; (1978):227-30. PubMed ID: 313321
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant intermittent chemo-immunotherapy of breast cancer. A prospective study.
Schreml W; Betzler M; Lang M; Lohrman HP; Kubitza P; Schlag P; Flad HD; Herfarth C; Heimpel H
Eur J Cancer (1965); 1980; Suppl 1():165-8. PubMed ID: 7032927
[No Abstract] [Full Text] [Related]
3. Adjuvant intermittent chemoimmunotherapy for primary breast cancer: a prospective study with immunologic follow-up.
Betzler M; Schreml W; Lang M; Lohrmann HP; Flad HD; Schlag P; Herfarth C; Heimpel H
Recent Results Cancer Res; 1982; 80():185-91. PubMed ID: 7036282
[TBL] [Abstract][Full Text] [Related]
4. Combination of levamisole immunotherapy and polychemotherapy in advanced breast cancer.
Klefström P
Cancer Treat Rep; 1980 Jan; 64(1):65-72. PubMed ID: 6991105
[TBL] [Abstract][Full Text] [Related]
5. Chemo-immunotherapy with levamisole in metastatic breast carcinoma: a controlled clinical trial.
Paterson AH; Edwards AM; Nutting M; Schinnour D; Takats L; McClelland A
Cancer Clin Trials; 1980; 3(1):5-10. PubMed ID: 6993035
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy of breast cancer (review of foreign literature)].
Liapis MA
Vopr Onkol; 1983; 29(8):68-74. PubMed ID: 6351428
[No Abstract] [Full Text] [Related]
7. Assessment of host immune response in breast cancer patients.
Akimoto M; Ishii H; Nakajima Y; Iwasaki H; Tan M; Abe R; Kasai M
Cancer Detect Prev; 1986; 9(3-4):311-7. PubMed ID: 3488806
[TBL] [Abstract][Full Text] [Related]
8. Impact of adjuvant chemo- and radiotherapy on the cellular immune system of breast cancer patients.
Mellios T; Ko HL; Beuth J
In Vivo; 2010; 24(2):227-30. PubMed ID: 20364000
[TBL] [Abstract][Full Text] [Related]
9. Deficiency of antibody-dependent cellular cytotoxicity and mitogen-induced cellular cytotoxicity effector cell function in patients with acute myelogenous leukemia in remission.
Zighelboim J
Cancer Res; 1979 Sep; 39(9):3357-62. PubMed ID: 314332
[TBL] [Abstract][Full Text] [Related]
10. [Disorders of the immune system in benign lesions and cancer of the breast].
Derevnina NA; Polevaia EB; Veskova TK; Trubcheninova LP; Bogatyrev VN
Vopr Onkol; 1989; 35(7):810-6. PubMed ID: 2788960
[TBL] [Abstract][Full Text] [Related]
11. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy.
Mozaffari F; Lindemalm C; Choudhury A; Granstam-Björneklett H; Helander I; Lekander M; Mikaelsson E; Nilsson B; Ojutkangas ML; Osterborg A; Bergkvist L; Mellstedt H
Br J Cancer; 2007 Jul; 97(1):105-11. PubMed ID: 17551492
[TBL] [Abstract][Full Text] [Related]
12. In vitro studies of axillary lymph node cells in patients with breast cancer.
Tsakraklides E; Tsakraklides V; Ashikari H; Rosen PP; Siegal FP; Robbins GF; Good RA
J Natl Cancer Inst; 1975 Mar; 54(3):549-56. PubMed ID: 1079055
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte functions of child patients with ALL (acute lymphoblastic leukemia) in remission.
Suzuki M
Jpn J Clin Oncol; 1984 Mar; 14(1):31-40. PubMed ID: 6231391
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy with decaris in the early stages of breast cancer].
Polevaia EB; Derevnina NA; Trubchaninova LP; Veskova TK
Vopr Onkol; 1988; 34(10):1182-8. PubMed ID: 3055672
[TBL] [Abstract][Full Text] [Related]
16. Study of B and T lymphocyte surface markers in breast cancer patients using anti-B and anti-T cell monoclonal antibodies.
Nowak JS; Lanzrein C
Neoplasma; 1984; 31(3):281-9. PubMed ID: 6610835
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
18. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
19. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant chemotherapy in breast cancer patients. Observations on psychological adjustment].
Lang M; Mergel H; Schreml W; Köhle K
MMW Munch Med Wochenschr; 1983 Mar; 125(10):190-2. PubMed ID: 6405206
[No Abstract] [Full Text] [Related]
[Next] [New Search]
